Observations on efficacy of irbesartan in treatment of chronic heart failure

AIM To observe the clinical efficacy of conventional treatment plus irbesartan in the treatment of patients with chronic heart failure（CHF）. METHODS A total of 78 CHF patients were randomly divided into two groups. The control group was given conventional treatment and the irbesartan group was given conventional treatment plus irbesartan. After 90 days’ treatment, the clinical efficacy, blood pressure (BP), heart rate (HR), cardio-thoracic ratio and echocardiography parameters were observed and compared between the 2 groups. RESULTS The efficiency of the irbesartan group was 88 percent, significantly higher than that of the control group (P<0.05). The heart function of the irbesartan group was significantly better improved than that of the control group(P<0.05) and fewer side effects were found in the irbesartan group. CONCLUSION Irbesartan is safe and effective in the treatment of CHF and can be used as first-line treatment for CHF.